^
    over1year
    A Study of BNC105P Combined With Ibrutinib (clinicaltrials.gov)
    P1, N=6, Completed, Dartmouth-Hitchcock Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Imbruvica (ibrutinib) • BNC105
    2years
    A Study of BNC105P Combined With Ibrutinib (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Dartmouth-Hitchcock Medical Center | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CCND1 overexpression
    |
    Imbruvica (ibrutinib) • BNC105
    almost3years
    Gene expression signature correlates with outcomes in metastatic renal cell carcinoma patients treated with everolimus alone or with a vascular disrupting agent. (PubMed, Mol Cancer Ther)
    Among 43 patients (52.4%) with low expression of an 18-gene signature, everolimus+BNC105P was associated with significantly longer mPFS compared to everolimus alone (10.4 vs 6.9 months, HR 0.49, 95%CI=0.24-1.002, p=0.047). These signatures warrant further validation to select patients who may benefit from everolimus alone or with a VDA.
    Clinical • Journal
    |
    ASXL1 (ASXL Transcriptional Regulator 1) • ERCC2 (Excision repair cross-complementation group 2) • DUSP6 (Dual specificity phosphatase 6)
    |
    everolimus • BNC105
    3years
    A Study of BNC105P Combined With Ibrutinib (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Dartmouth-Hitchcock Medical Center | Recruiting --> Active, not recruiting | N=15 --> 6 | Trial primary completion date: Mar 2021 --> Dec 2021
    Clinical • Enrollment closed • Enrollment change • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CCND1 overexpression
    |
    Imbruvica (ibrutinib) • BNC105
    over3years
    A Study of BNC105P Combined With Ibrutinib (clinicaltrials.gov)
    P1, N=15, Recruiting, Dartmouth-Hitchcock Medical Center | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2020 --> Mar 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CCND1 overexpression
    |
    Imbruvica (ibrutinib) • BNC105
    almost4years
    A Study of BNC105P Combined With Ibrutinib (clinicaltrials.gov)
    P1, N=15, Recruiting, Dartmouth-Hitchcock Medical Center | Trial primary completion date: Feb 2020 --> Sep 2020
    Clinical • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CCND1 overexpression
    |
    Imbruvica (ibrutinib) • BNC105